MARKET INSIGHTS
The global CAR T-Cell Therapy market was valued at USD 3.73 billion in 2023 and is projected to reach USD 21.91 billion by 2030, exhibiting a remarkable CAGR of 28.2% during the forecast period.
CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy) represents a revolutionary advancement in immunotherapy, where a patient's own T cells are genetically modified to express specific receptors targeting cancer cells. This personalized treatment approach has demonstrated exceptional efficacy against hematological malignancies, particularly in refractory cases of acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). The technology is now being actively explored for potential applications in solid tumors.
North America currently dominates the market with over 65% share, while CD19-targeted therapies account for more than 90% of all CAR-T treatments. The market is highly consolidated, with Gilead Sciences, Novartis, and Bristol-Myers Squibb collectively holding over 99% market share. While the therapy's transformative potential drives rapid adoption, its high cost (often exceeding USD 400,000 per treatment) and complex manufacturing process present significant barriers to broader accessibility.
MARKET DYNAMICS
MARKET DRIVERS
Unprecedented Efficacy in Hematologic Cancers Fuels Market Expansion
The remarkable success of CAR T-cell therapy in treating relapsed or refractory hematologic malignancies remains the primary driver of market growth. Clinical trials have demonstrated durable remission rates exceeding 80% in certain B-cell malignancies, transforming treatment paradigms for conditions like diffuse large B-cell lymphoma (DLBCL). With over 50,000 new DLBCL cases annually in the United States alone, this breakthrough addresses a critical unmet medical need. The therapy's ability to achieve long-term disease control in previously treatment-resistant patients continues to drive adoption despite high costs.
Advancements in Manufacturing Efficiency Accelerate Market Penetration
Recent technological innovations have significantly reduced vein-to-vein time from 3-4 weeks to under 7 days in some next-generation processes. Automated closed-system bioreactors now achieve 95% cell viability rates compared to traditional manual methods. Major players have invested over $2 billion collectively in manufacturing scale-up initiatives since 2020, addressing previous bottlenecks in production capacity. These improvements enhance therapy accessibility while reducing costs through economies of scale.
Additionally, the emergence of allogeneic "off-the-shelf" CAR-T products in late-stage clinical development promises to revolutionize treatment logistics. Unlike autologous therapies requiring custom manufacturing for each patient, these universal cell products could reduce costs by 40-60% while enabling immediate treatment availability.
MARKET RESTRAINTS
Prohibitive Treatment Costs Limit Widespread Adoption
With price tags exceeding $400,000 per treatment course, CAR-T therapy remains financially inaccessible for many healthcare systems worldwide. The complex manufacturing workflow contributes 60-70% of total costs, involving specialized cleanrooms, viral vector production, and intensive quality control processes. In emerging markets, limited reimbursement frameworks exacerbate affordability challenges - currently fewer than 15 countries provide comprehensive coverage for these therapies.
Safety Concerns and Toxicity Management Hinder Broader Application
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) occur in 40-50% of patients receiving CD19-directed CAR-T therapies. While tocilizumab and corticosteroids have improved management of these side effects, severe cases still require intensive care in 15-20% of administrations. These safety profiles currently restrict treatment to specialized centers with advanced supportive care capabilities, limiting geographic accessibility. The mortality rate from treatment-related complications remains at 2-4% across approved products, creating hesitation among some clinicians.
MARKET OPPORTUNITIES
Expansion into Solid Tumors Represents Multi-Billion Dollar Potential
Over 150 clinical trials currently investigate CAR-T applications in solid tumors including glioblastoma, pancreatic, and ovarian cancers. While hematologic malignancies represent a $15 billion addressable market, successful expansion into solid tumors could unlock a potential $50+ billion market opportunity. Novel engineering approaches like tumor-microenvironment modulating CARs and dual-targeting constructs show promising early-phase results against traditionally resistant cancers.
Emerging Asian Markets Offer Untapped Growth Potential
China's newly established Fast Track Approval Pathway has accelerated CAR-T adoption, with the market projected to grow at 35% CAGR through 2030. Domestic players now account for 40% of global CAR-T clinical trials, supported by government-backed research initiatives. Similar growth trajectories are emerging in South Korea and Singapore, where national healthcare systems are establishing specialized treatment centers and reimbursement frameworks.
MARKET CHALLENGES
Regulatory Heterogeneity Complicates Global Market Access
Divergent regulatory requirements across major markets create significant barriers to commercialization. While the FDA and EMA have established comprehensive frameworks, approval timelines still vary by 6-12 months between regions. Many emerging economies lack specialized regulatory pathways for advanced therapies, requiring sponsors to navigate complex equivalence processes. These inconsistencies contribute to delayed market entry and increased compliance costs for manufacturers.
Manufacturing Complexity Threatens Supply Chain Stability
The CAR-T production process involves 40+ critical quality attributes across viral vector production, cell expansion, and final product formulation. Single batches frequently fail release testing due to variability in starting material or process deviations - industry benchmarks indicate 10-15% failure rates for autologous products. Supply chain vulnerabilities were exposed during the pandemic when logistical disruptions caused 20-30% delays in patient treatment initiation. Developing robust, distributed manufacturing networks remains a persistent challenge for the industry.
Segment Analysis:
By Type
CD19-Targeted CAR-T Therapy Dominates the Market Due to High Efficacy in Hematological Malignancies
The global CAR T-Cell Therapy market is segmented based on target antigen types into:
-
CD19-Targeted CAR-T Therapy
-
BCMA-Targeted CAR-T Therapy
-
Others (including CD22, CD30, and novel targets)
By Application
Lymphoma Treatment Leads the Market Due to Significant Patient Population and Regulatory Approvals
The market is segmented based on application into:
By End User
Hospitals and Cancer Centers Dominate as Primary Treatment Facilities
The market is segmented based on end users into:
-
Hospitals and Cancer Centers
-
Specialty Clinics
-
Academic and Research Institutes
-
Biopharmaceutical Companies
COMPETITIVE LANDSCAPE
Key Industry Players
Pharma Giants and Emerging Biotechs Compete in the High-Stakes CAR-T Arena
The global CAR T-Cell Therapy market is heavily concentrated among a few established pharmaceutical players, with Gilead Sciences, Novartis, and Bristol-Myers Squibb collectively controlling over 99% of the market share as of 2023. Gilead's subsidiary Kite Pharma leads this space, accounting for more than 50% of the total market revenue through its FDA-approved therapies Yescarta® and Tecartus®. This dominance stems from first-mover advantage in commercializing CAR-T treatments and establishing robust manufacturing capabilities.
Novartis maintains strong market positioning with its breakthrough therapy Kymriah®, the first FDA-approved CAR-T treatment. The company continues to invest heavily in expanding its therapeutic indications and improving manufacturing efficiency. Meanwhile, Bristol-Myers Squibb has strengthened its position through strategic acquisitions, most notably its purchase of Celgene which brought the approved therapy Breyanzi® into its portfolio.
Beyond these three market leaders, several Chinese biotech firms including JW Therapeutics and FOSUNKite are making significant inroads, particularly in the Asian market. These companies benefit from regional regulatory advantages and government support for domestic biopharmaceutical innovation. Their growth is further propelled by partnerships with academic institutions and streamlined approval processes within China's healthcare system.
The competitive intensity is further heightened by numerous biotech companies in late-stage clinical development. CARsgen Therapeutics and Autolus Therapeutics are among the most promising pipeline players, developing next-generation CAR-T therapies targeting solid tumors. These emerging innovators are attracting substantial venture capital and forming strategic collaborations with larger pharma companies seeking to expand their cellular therapy portfolios.
List of Key CAR T-Cell Therapy Companies Profiled
CAR T-CELL THERAPY MARKET TRENDS
Expansion into Solid Tumor Treatments to Drive Market Growth
While CAR T-cell therapy has demonstrated exceptional success in hematologic malignancies, its application in solid tumors represents the next frontier for market expansion. Currently, over 90% of approved CAR-T therapies target CD19 or BCMA antigens in blood cancers, but significant research efforts are underway to overcome the unique challenges of solid tumors, including tumor microenvironment suppression and target antigen heterogeneity. Recent clinical trials exploring mesothelin, HER2, and GPC3-targeted CAR-T therapies have shown promising early results, with several phase II trials reporting objective response rates between 30-50% in selected solid tumor types. The anticipated approval of solid tumor CAR-T therapies could potentially triple the eligible patient population by 2030.
Other Trends
Manufacturing Process Innovations
The industry is witnessing accelerated development of next-generation manufacturing platforms to address current limitations in production scalability and cost. While traditional autologous CAR-T therapies require 2-3 weeks for manufacturing, new automated closed-system technologies have reduced processing times by 40-50% in pilot programs. Allogeneic "off-the-shelf" CAR-T products, currently in late-stage clinical trials, promise to revolutionize treatment accessibility by eliminating the need for patient-specific manufacturing. These advancements are critical as the market strives to reduce the current average treatment cost of $350,000-$475,000 per patient.
Regulatory Landscape Evolution
Global regulatory agencies are developing tailored frameworks to accommodate the unique characteristics of CAR-T therapies. The FDA's recent draft guidance on manufacturing comparability for CAR-T products reflects growing recognition of the need for flexible regulations that don't compromise patient safety. In parallel, regulatory harmonization efforts between the US, EU, and Asian markets are reducing approval timelines for second-generation products by approximately 6-9 months. These developments are particularly impactful as 65% of ongoing CAR-T clinical trials originate from biotech companies relying on streamlined pathways for market entry.
Regional Analysis: CAR T-Cell Therapy Market
North America
North America dominates the CAR T-Cell Therapy market, accounting for over 65% of global revenue, with the U.S. as the primary driver. The region benefits from high healthcare expenditure, favorable reimbursement policies, and strong FDA support for breakthrough therapies like Yescarta (Gilead Sciences) and Kymriah (Novartis). While treatment costs remain prohibitive (>$400,000 per dose), expanding insurance coverage and established manufacturing hubs enable accessibility. However, infrastructure limitations for managing severe side effects and competition from biosimilars present challenges. Recent developments include Gilead's FDA approval for earlier-line lymphoma treatment in 2023, potentially expanding addressable markets.
Europe
Europe shows steady growth in CAR-T adoption, though slower than North America due to stringent EMA approval processes and budget constraints in single-payer systems. Germany and France lead in utilization, with academic centers pioneering next-generation therapies. The EU's Horizon Europe program funds research addressing manufacturing bottlenecks – a critical constraint given the therapy's personalized nature. While reimbursement remains inconsistent across countries, Germany's recent inclusion of CAR-T in DRG coding signals progress. Emerging players like Autolus Therapeutics showcase Europe's R&D potential, though commercial scalability lags behind U.S. counterparts.
Asia-Pacific
The Asia-Pacific region demonstrates the fastest growth potential, driven by China's rapidly expanding biotechnology sector. Local players like JW Therapeutics and CARsgen have launched domestically developed therapies at lower price points (~$150,000), addressing affordability barriers. Japan's PMDA has accelerated approvals, including Bristol-Myers Squibb's Breyanzi in 2022. However, most countries lack specialized treatment centers capable of managing cytokine release syndrome, restricting adoption. India faces additional challenges with intellectual property protections, though policy reforms and hospital alliances with global Pharma indicate future opportunities. The region's large patient pool makes it attractive for clinical trials, with over 40 CAR-T studies active across China.
South America
South America represents a nascent market where CAR-T adoption is constrained by economic instability and fragmented healthcare systems. Brazil shows the most promise, with ANVISA approving Kymriah in 2022 and select private hospitals offering treatment. Argentina and Chile have initiated early access programs, but public funding remains inadequate for widespread use. The region struggles with cold-chain logistics for cell transport and lacks local manufacturing capabilities. While medical tourism to the U.S. occurs among affluent patients, domestic clinical collaborations – such as the São Paulo Cancer Center's tie-up with Novartis – hint at gradual market development.
Middle East & Africa
The MEA region exhibits stark disparities in CAR-T accessibility, with Israel and UAE emerging as early adopters while most African nations lack basic infrastructure. Saudi Arabia's Vision 2030 healthcare investments include specialized cancer centers capable of administering therapy, though patient volumes remain low. Turkey has approved treatments but faces currency-related procurement challenges. South Africa's Mediclinic group began offering CAR-T in 2023 through European partnerships. Across Africa, high HIV prevalence complicates T-cell harvesting, and lack of cleanroom facilities prevents local therapy production. Philanthropic initiatives and hospital twinning programs may enable future capacity building.
Report Scope
This market research report offers a holistic overview of global and regional CAR T-Cell Therapy markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Key Coverage Areas:
-
✅ Market Overview
-
✅ Segmentation Analysis
-
By product type (CD19-Targeted, BCMA-Targeted)
-
By application (Lymphoma, Multiple Myeloma)
-
By end-user (Hospitals, Specialty Clinics)
-
By distribution channel (Direct Sales, Third-Party)
-
✅ Regional Insights
-
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
-
Country-level data for key markets
-
✅ Competitive Landscape
-
Company profiles and market share analysis
-
Key strategies: M&A, partnerships, expansions
-
Product portfolio and pricing strategies
-
✅ Technology & Innovation
-
Emerging technologies and R&D trends
-
Next-generation CAR-T development
-
Impact of AI and automation in manufacturing
-
✅ Market Dynamics
-
Key drivers supporting market growth
-
Restraints and potential risk factors
-
Supply chain trends and challenges
-
✅ Opportunities & Recommendations
-
✅ Stakeholder Insights
-
Target audience includes biopharma companies, healthcare providers, investors, regulators, and policymakers
FREQUENTLY ASKED QUESTIONS:
What is the current market size of Global CAR T-Cell Therapy Market?
-> The global CAR T-Cell Therapy market was valued at USD 3,732 million in 2023 and is projected to reach USD 21,910 million by 2030, growing at a CAGR of 28.2%.
Which key companies operate in Global CAR T-Cell Therapy Market?
-> Key players include Gilead Sciences (50%+ market share), Novartis, Bristol-Myers Squibb, J&J, and JW Therapeutics, with the top 3 companies holding over 99% market share.
What are the key growth drivers?
-> Key growth drivers include rising cancer prevalence, success in hematological malignancies, and increasing investment in cell therapy R&D.
Which region dominates the market?
-> North America dominates with over 65% market share, while Asia-Pacific shows the fastest growth potential.
What are the emerging trends?
-> Emerging trends include development for solid tumors, off-the-shelf CAR-T products, and AI-driven manufacturing optimization.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 CAR T-Cell Therapy Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 Global CAR T-Cell Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global CAR T-Cell Therapy Overall Market Size
2.1 Global CAR T-Cell Therapy Market Size: 2023 VS 2030
2.2 Global CAR T-Cell Therapy Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top CAR T-Cell Therapy Players in Global Market
3.2 Top Global CAR T-Cell Therapy Companies Ranked by Revenue
3.3 Global CAR T-Cell Therapy Revenue by Companies
3.4 Top 3 and Top 5 CAR T-Cell Therapy Companies in Global Market, by Revenue in 2023
3.5 Global Companies CAR T-Cell Therapy Product Type
3.6 Tier 1, Tier 2, and Tier 3 CAR T-Cell Therapy Players in Global Market
3.6.1 List of Global Tier 1 CAR T-Cell Therapy Companies
3.6.2 List of Global Tier 2 and Tier 3 CAR T-Cell Therapy Companies
4 Sights by Product
4.1 Overview
4.1.1 Segmentation by Type - Global CAR T-Cell Therapy Market Size Markets, 2023 & 2030
4.1.2 CD19 - Targeted
4.1.3 BCMA - Targeted
4.2 Segmentation by Type - Global CAR T-Cell Therapy Revenue & Forecasts
4.2.1 Segmentation by Type - Global CAR T-Cell Therapy Revenue, 2019-2024
4.2.2 Segmentation by Type - Global CAR T-Cell Therapy Revenue, 2025-2030
4.2.3 Segmentation by Type - Global CAR T-Cell Therapy Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 Segmentation by Application - Global CAR T-Cell Therapy Market Size, 2023 & 2030
5.1.2 Lymphoma
5.1.3 Multiple Myeloma
5.2 Segmentation by Application - Global CAR T-Cell Therapy Revenue & Forecasts
5.2.1 Segmentation by Application - Global CAR T-Cell Therapy Revenue, 2019-2024
5.2.2 Segmentation by Application - Global CAR T-Cell Therapy Revenue, 2025-2030
5.2.3 Segmentation by Application - Global CAR T-Cell Therapy Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global CAR T-Cell Therapy Market Size, 2023 & 2030
6.2 By Region - Global CAR T-Cell Therapy Revenue & Forecasts
6.2.1 By Region - Global CAR T-Cell Therapy Revenue, 2019-2024
6.2.2 By Region - Global CAR T-Cell Therapy Revenue, 2025-2030
6.2.3 By Region - Global CAR T-Cell Therapy Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America CAR T-Cell Therapy Revenue, 2019-2030
6.3.2 United States CAR T-Cell Therapy Market Size, 2019-2030
6.3.3 Canada CAR T-Cell Therapy Market Size, 2019-2030
6.3.4 Mexico CAR T-Cell Therapy Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe CAR T-Cell Therapy Revenue, 2019-2030
6.4.2 Germany CAR T-Cell Therapy Market Size, 2019-2030
6.4.3 France CAR T-Cell Therapy Market Size, 2019-2030
6.4.4 U.K. CAR T-Cell Therapy Market Size, 2019-2030
6.4.5 Italy CAR T-Cell Therapy Market Size, 2019-2030
6.4.6 Russia CAR T-Cell Therapy Market Size, 2019-2030
6.4.7 Nordic Countries CAR T-Cell Therapy Market Size, 2019-2030
6.4.8 Benelux CAR T-Cell Therapy Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia CAR T-Cell Therapy Revenue, 2019-2030
6.5.2 China CAR T-Cell Therapy Market Size, 2019-2030
6.5.3 Japan CAR T-Cell Therapy Market Size, 2019-2030
6.5.4 South Korea CAR T-Cell Therapy Market Size, 2019-2030
6.5.5 Southeast Asia CAR T-Cell Therapy Market Size, 2019-2030
6.5.6 India CAR T-Cell Therapy Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America CAR T-Cell Therapy Revenue, 2019-2030
6.6.2 Brazil CAR T-Cell Therapy Market Size, 2019-2030
6.6.3 Argentina CAR T-Cell Therapy Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa CAR T-Cell Therapy Revenue, 2019-2030
6.7.2 Turkey CAR T-Cell Therapy Market Size, 2019-2030
6.7.3 Israel CAR T-Cell Therapy Market Size, 2019-2030
6.7.4 Saudi Arabia CAR T-Cell Therapy Market Size, 2019-2030
6.7.5 UAE CAR T-Cell Therapy Market Size, 2019-2030
7 Companies Profiles
7.1 Novartis
7.1.1 Novartis Corporate Summary
7.1.2 Novartis Business Overview
7.1.3 Novartis CAR T-Cell Therapy Major Product Offerings
7.1.4 Novartis CAR T-Cell Therapy Revenue in Global Market (2019-2024)
7.1.5 Novartis Key News & Latest Developments
7.2 Gilead Sciences
7.2.1 Gilead Sciences Corporate Summary
7.2.2 Gilead Sciences Business Overview
7.2.3 Gilead Sciences CAR T-Cell Therapy Major Product Offerings
7.2.4 Gilead Sciences CAR T-Cell Therapy Revenue in Global Market (2019-2024)
7.2.5 Gilead Sciences Key News & Latest Developments
7.3 Bristol-Myers Squibb
7.3.1 Bristol-Myers Squibb Corporate Summary
7.3.2 Bristol-Myers Squibb Business Overview
7.3.3 Bristol-Myers Squibb CAR T-Cell Therapy Major Product Offerings
7.3.4 Bristol-Myers Squibb CAR T-Cell Therapy Revenue in Global Market (2019-2024)
7.3.5 Bristol-Myers Squibb Key News & Latest Developments
7.4 J & J
7.4.1 J & J Corporate Summary
7.4.2 J & J Business Overview
7.4.3 J & J CAR T-Cell Therapy Major Product Offerings
7.4.4 J & J CAR T-Cell Therapy Revenue in Global Market (2019-2024)
7.4.5 J & J Key News & Latest Developments
7.5 JW Therapeutics
7.5.1 JW Therapeutics Corporate Summary
7.5.2 JW Therapeutics Business Overview
7.5.3 JW Therapeutics CAR T-Cell Therapy Major Product Offerings
7.5.4 JW Therapeutics CAR T-Cell Therapy Revenue in Global Market (2019-2024)
7.5.5 JW Therapeutics Key News & Latest Developments
7.6 FOSUNKite
7.6.1 FOSUNKite Corporate Summary
7.6.2 FOSUNKite Business Overview
7.6.3 FOSUNKite CAR T-Cell Therapy Major Product Offerings
7.6.4 FOSUNKite CAR T-Cell Therapy Revenue in Global Market (2019-2024)
7.6.5 FOSUNKite Key News & Latest Developments
7.7 CARsgen Therapeutics (Pipeline)
7.7.1 CARsgen Therapeutics (Pipeline) Corporate Summary
7.7.2 CARsgen Therapeutics (Pipeline) Business Overview
7.7.3 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Major Product Offerings
7.7.4 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Revenue in Global Market (2019-2024)
7.7.5 CARsgen Therapeutics (Pipeline) Key News & Latest Developments
7.8 Autolus Therapeutics(Pipeline)
7.8.1 Autolus Therapeutics(Pipeline) Corporate Summary
7.8.2 Autolus Therapeutics(Pipeline) Business Overview
7.8.3 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Major Product Offerings
7.8.4 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Revenue in Global Market (2019-2024)
7.8.5 Autolus Therapeutics(Pipeline) Key News & Latest Developments
7.9 Sorrento Therapeutics(Pipeline)
7.9.1 Sorrento Therapeutics(Pipeline) Corporate Summary
7.9.2 Sorrento Therapeutics(Pipeline) Business Overview
7.9.3 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Major Product Offerings
7.9.4 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Revenue in Global Market (2019-2024)
7.9.5 Sorrento Therapeutics(Pipeline) Key News & Latest Developments
7.10 Mustang Bio(Pipeline)
7.10.1 Mustang Bio(Pipeline) Corporate Summary
7.10.2 Mustang Bio(Pipeline) Business Overview
7.10.3 Mustang Bio(Pipeline) CAR T-Cell Therapy Major Product Offerings
7.10.4 Mustang Bio(Pipeline) CAR T-Cell Therapy Revenue in Global Market (2019-2024)
7.10.5 Mustang Bio(Pipeline) Key News & Latest Developments
7.11 Bluebird Bio(Pipeline)
7.11.1 Bluebird Bio(Pipeline) Corporate Summary
7.11.2 Bluebird Bio(Pipeline) Business Overview
7.11.3 Bluebird Bio(Pipeline) CAR T-Cell Therapy Major Product Offerings
7.11.4 Bluebird Bio(Pipeline) CAR T-Cell Therapy Revenue in Global Market (2019-2024)
7.11.5 Bluebird Bio(Pipeline) Key News & Latest Developments
7.12 Cellectis(Pipeline)
7.12.1 Cellectis(Pipeline) Corporate Summary
7.12.2 Cellectis(Pipeline) Business Overview
7.12.3 Cellectis(Pipeline) CAR T-Cell Therapy Major Product Offerings
7.12.4 Cellectis(Pipeline) CAR T-Cell Therapy Revenue in Global Market (2019-2024)
7.12.5 Cellectis(Pipeline) Key News & Latest Developments
7.13 Allogene Therapeutics(Pipeline)
7.13.1 Allogene Therapeutics(Pipeline) Corporate Summary
7.13.2 Allogene Therapeutics(Pipeline) Business Overview
7.13.3 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Major Product Offerings
7.13.4 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Revenue in Global Market (2019-2024)
7.13.5 Allogene Therapeutics(Pipeline) Key News & Latest Developments
7.14 Celyad(Pipeline)
7.14.1 Celyad(Pipeline) Corporate Summary
7.14.2 Celyad(Pipeline) Business Overview
7.14.3 Celyad(Pipeline) CAR T-Cell Therapy Major Product Offerings
7.14.4 Celyad(Pipeline) CAR T-Cell Therapy Revenue in Global Market (2019-2024)
7.14.5 Celyad(Pipeline) Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. CAR T-Cell Therapy Market Opportunities & Trends in Global Market
Table 2. CAR T-Cell Therapy Market Drivers in Global Market
Table 3. CAR T-Cell Therapy Market Restraints in Global Market
Table 4. Key Players of CAR T-Cell Therapy in Global Market
Table 5. Top CAR T-Cell Therapy Players in Global Market, Ranking by Revenue (2023)
Table 6. Global CAR T-Cell Therapy Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global CAR T-Cell Therapy Revenue Share by Companies, 2019-2024
Table 8. Global Companies CAR T-Cell Therapy Product Type
Table 9. List of Global Tier 1 CAR T-Cell Therapy Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 CAR T-Cell Therapy Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. Segmentation by Type – Global CAR T-Cell Therapy Revenue, (US$, Mn), 2023 & 2030
Table 12. Segmentation by Type - Global CAR T-Cell Therapy Revenue (US$, Mn), 2019-2024
Table 13. Segmentation by Type - Global CAR T-Cell Therapy Revenue (US$, Mn), 2025-2030
Table 14. Segmentation by Application– Global CAR T-Cell Therapy Revenue, (US$, Mn), 2023 & 2030
Table 15. Segmentation by Application - Global CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2024
Table 16. Segmentation by Application - Global CAR T-Cell Therapy Revenue, (US$, Mn), 2025-2030
Table 17. By Region– Global CAR T-Cell Therapy Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2024
Table 19. By Region - Global CAR T-Cell Therapy Revenue, (US$, Mn), 2025-2030
Table 20. By Country - North America CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America CAR T-Cell Therapy Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe CAR T-Cell Therapy Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia CAR T-Cell Therapy Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America CAR T-Cell Therapy Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa CAR T-Cell Therapy Revenue, (US$, Mn), 2025-2030
Table 30. Novartis Corporate Summary
Table 31. Novartis CAR T-Cell Therapy Product Offerings
Table 32. Novartis CAR T-Cell Therapy Revenue (US$, Mn) & (2019-2024)
Table 33. Novartis Key News & Latest Developments
Table 34. Gilead Sciences Corporate Summary
Table 35. Gilead Sciences CAR T-Cell Therapy Product Offerings
Table 36. Gilead Sciences CAR T-Cell Therapy Revenue (US$, Mn) & (2019-2024)
Table 37. Gilead Sciences Key News & Latest Developments
Table 38. Bristol-Myers Squibb Corporate Summary
Table 39. Bristol-Myers Squibb CAR T-Cell Therapy Product Offerings
Table 40. Bristol-Myers Squibb CAR T-Cell Therapy Revenue (US$, Mn) & (2019-2024)
Table 41. Bristol-Myers Squibb Key News & Latest Developments
Table 42. J & J Corporate Summary
Table 43. J & J CAR T-Cell Therapy Product Offerings
Table 44. J & J CAR T-Cell Therapy Revenue (US$, Mn) & (2019-2024)
Table 45. J & J Key News & Latest Developments
Table 46. JW Therapeutics Corporate Summary
Table 47. JW Therapeutics CAR T-Cell Therapy Product Offerings
Table 48. JW Therapeutics CAR T-Cell Therapy Revenue (US$, Mn) & (2019-2024)
Table 49. JW Therapeutics Key News & Latest Developments
Table 50. FOSUNKite Corporate Summary
Table 51. FOSUNKite CAR T-Cell Therapy Product Offerings
Table 52. FOSUNKite CAR T-Cell Therapy Revenue (US$, Mn) & (2019-2024)
Table 53. FOSUNKite Key News & Latest Developments
Table 54. CARsgen Therapeutics (Pipeline) Corporate Summary
Table 55. CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Product Offerings
Table 56. CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Revenue (US$, Mn) & (2019-2024)
Table 57. CARsgen Therapeutics (Pipeline) Key News & Latest Developments
Table 58. Autolus Therapeutics(Pipeline) Corporate Summary
Table 59. Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Product Offerings
Table 60. Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Revenue (US$, Mn) & (2019-2024)
Table 61. Autolus Therapeutics(Pipeline) Key News & Latest Developments
Table 62. Sorrento Therapeutics(Pipeline) Corporate Summary
Table 63. Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Product Offerings
Table 64. Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Revenue (US$, Mn) & (2019-2024)
Table 65. Sorrento Therapeutics(Pipeline) Key News & Latest Developments
Table 66. Mustang Bio(Pipeline) Corporate Summary
Table 67. Mustang Bio(Pipeline) CAR T-Cell Therapy Product Offerings
Table 68. Mustang Bio(Pipeline) CAR T-Cell Therapy Revenue (US$, Mn) & (2019-2024)
Table 69. Mustang Bio(Pipeline) Key News & Latest Developments
Table 70. Bluebird Bio(Pipeline) Corporate Summary
Table 71. Bluebird Bio(Pipeline) CAR T-Cell Therapy Product Offerings
Table 72. Bluebird Bio(Pipeline) CAR T-Cell Therapy Revenue (US$, Mn) & (2019-2024)
Table 73. Bluebird Bio(Pipeline) Key News & Latest Developments
Table 74. Cellectis(Pipeline) Corporate Summary
Table 75. Cellectis(Pipeline) CAR T-Cell Therapy Product Offerings
Table 76. Cellectis(Pipeline) CAR T-Cell Therapy Revenue (US$, Mn) & (2019-2024)
Table 77. Cellectis(Pipeline) Key News & Latest Developments
Table 78. Allogene Therapeutics(Pipeline) Corporate Summary
Table 79. Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Product Offerings
Table 80. Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Revenue (US$, Mn) & (2019-2024)
Table 81. Allogene Therapeutics(Pipeline) Key News & Latest Developments
Table 82. Celyad(Pipeline) Corporate Summary
Table 83. Celyad(Pipeline) CAR T-Cell Therapy Product Offerings
Table 84. Celyad(Pipeline) CAR T-Cell Therapy Revenue (US$, Mn) & (2019-2024)
Table 85. Celyad(Pipeline) Key News & Latest Developments
List of Figures
Figure 1. CAR T-Cell Therapy Product Picture
Figure 2. CAR T-Cell Therapy Segment by Type in 2023
Figure 3. CAR T-Cell Therapy Segment by Application in 2023
Figure 4. Global CAR T-Cell Therapy Market Overview: 2022
Figure 5. Key Caveats
Figure 6. Global CAR T-Cell Therapy Market Size: 2023 VS 2030 (US$, Mn)
Figure 7. Global CAR T-Cell Therapy Revenue: 2019-2030 (US$, Mn)
Figure 8. The Top 3 and 5 Players Market Share by CAR T-Cell Therapy Revenue in 2023
Figure 9. Segmentation by Type – Global CAR T-Cell Therapy Revenue, (US$, Mn), 2023 & 2030
Figure 10. Segmentation by Type - Global CAR T-Cell Therapy Revenue Market Share, 2019-2030
Figure 11. Segmentation by Application – Global CAR T-Cell Therapy Revenue, (US$, Mn), 2023 & 2030
Figure 12. Segmentation by Application - Global CAR T-Cell Therapy Revenue Market Share, 2019-2030
Figure 13. By Region - Global CAR T-Cell Therapy Revenue Market Share, 2019-2030
Figure 14. By Country - North America CAR T-Cell Therapy Revenue Market Share, 2019-2030
Figure 15. United States CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 16. Canada CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 17. Mexico CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 18. By Country - Europe CAR T-Cell Therapy Revenue Market Share, 2019-2030
Figure 19. Germany CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 20. France CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 21. U.K. CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 22. Italy CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 23. Russia CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 24. Nordic Countries CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 25. Benelux CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 26. By Region - Asia CAR T-Cell Therapy Revenue Market Share, 2019-2030
Figure 27. China CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 28. Japan CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 29. South Korea CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 30. Southeast Asia CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 31. India CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 32. By Country - South America CAR T-Cell Therapy Revenue Market Share, 2019-2030
Figure 33. Brazil CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 34. Argentina CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 35. By Country - Middle East & Africa CAR T-Cell Therapy Revenue Market Share, 2019-2030
Figure 36. Turkey CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 37. Israel CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 38. Saudi Arabia CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 39. UAE CAR T-Cell Therapy Revenue, (US$, Mn), 2019-2030
Figure 40. Novartis CAR T-Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 41. Gilead Sciences CAR T-Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Bristol-Myers Squibb CAR T-Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. J & J CAR T-Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. JW Therapeutics CAR T-Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. FOSUNKite CAR T-Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Mustang Bio(Pipeline) CAR T-Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Bluebird Bio(Pipeline) CAR T-Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. Cellectis(Pipeline) CAR T-Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 53. Celyad(Pipeline) CAR T-Cell Therapy Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
